We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based casecontrol study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P ¼ 5.37 Â 10 À8 ; multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.
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Pancreatic cancer has one of the highest mortality rates of any cancer, with an estimated 5-year relative survival rate of o5% (refs. 1,2). Currently, there is not an effective screening test for this malignancy, and by the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of type 2 diabetes and cigarette smoking 3 . Studies have also suggested an increased risk of pancreatic cancer within families with hereditary pancreatitis 4, 5 . In addition, it has been estimated that a small proportion of pancreatic cancers are due to highly penetrant germline mutations 6 . Prior studies have suggested a genetic contribution to pancreatic cancer, but there has been limited success in replicating common variants reported to be associated with this disease. Here we report a genome-wide association study (GWAS) to identify common variants associated with pancreatic cancer.
We conducted a GWAS in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts (the American Cancer Society Cancer Prevention Study II (ref. 7) , the AlphaTocopherol, Beta-Carotene Cancer Prevention Study 8 Table 2) .
After quality control of genotypes using the HumanHap500 chip, 558,542 SNPs were available for analysis. We fit a logistic regression model for genotype trend effects (1 degree of freedom (d.f.)), adjusting for study, age, sex, ancestry and the top five principal components of population stratification (Online Methods). The quantile-quantile plot did not demonstrate a systematic deviation from the expected distribution, minimizing the likelihood of systematic genotype error or bias due to underlying population substructure ( Supplementary  Fig. 1 ). The results of the GWAS are shown in Figure 1a . Because of the potential for survivor bias in case-control studies owing to rapid mortality, we also analyzed the GWAS for the cohort studies alone (that is, excluding the Mayo participants) (Fig. 1b) .
We conducted a fast track replication of SNPs from three regions (9q34, 7q36 and a gene desert on 15q14) in eight case-control studies (four hospital-based and four population-based). At least two SNPs per region ranked among the lowest 25 P values in the initial GWAS: (i) rs505922, rs495828, rs657152 and rs630014 (ranked 2, 3, 8 and 17) on 9q34, which includes the ABO gene, (ii) rs167020, rs172310 and rs288746 (ranked 6, 10 and 89) on 7q36, which includes SHH (sonic hedgehog homolog), and (iii) rs8028529, rs4130461 and rs4459505 (ranked 1, 18 and 26) in the gene desert on 15q14 (Table 1) .
In a combined analysis of individuals of European background 24 , the strongest association with pancreatic cancer below the threshold for genome-wide significance 25 was for a locus marked by rs505922 on chromosome 9q34, located within the first intron of ABO, a welldescribed blood group gene (P ¼ 5.37 Â 10 À8 , trend model; heterozygous odds ratio (OR Het ) ¼ 1.20, 95% confidence interval (c.i.)
1.12-1.28; homozygous odds ratio (OR Hom ) ¼ 1.44, 95% c.i. 1.26-1.63). We observed a comparable result when we included all ethnic groups in stage 1 (P ¼ 2.61 Â 10 À8 ; Supplementary Table 3 ). In the case-control replication set, we genotyped a second SNP, rs687621 (r 2 ¼ 1 with rs505922 in HapMap CEU and r 2 ¼ 0.91 in stage 2 controls), located 12 kb centromeric in intron 2; this confirmed the signal at the locus (P ¼ 1.57 Â 10 À4 in the stage 2 case-control studies only). In the combined analysis, we observed a comparably strong signal for rs630014 (P ¼ 1.58 Â 10 À7 ; OR Het ¼ 0.85, OR Hom ¼ 0.71), which resides within 500 bp of rs505922 and is in linkage disequilibrium (LD) (r 2 ¼ 0.52 in HapMap CEU and 0.40 in PanScan GWAS European controls). After adjusting for rs505922, none of the remaining SNPs in ABO was significant at P o 0.01. The SNPs reside in a haplotype block that encompasses the proximal promoter and introns 1 and 2 (Fig. 2) .
Blood groups were first described by Karl Landsteiner in 1900, but the structure of the ABO antigens and their biosynthesis remained elusive until after 1950. The ABO gene encodes a glycosyltransferase that catalyzes the transfer of carbohydrates to the H antigen, forming the antigenic structure of the ABO blood groups. The proteins encoded by the A and B alleles of ABO differ minimally in amino acid sequence but catalyze the transfer of different carbohydrates (N-acetylgalactosamine or galactose) onto the H antigen to form the A or B antigens. Individuals with the O blood group do not produce either the A or B antigens because of a single-base deletion.
Our findings are notable because multiple studies, mainly from the 1950s and 1960s, reported an association between ABO blood type and gastrointestinal cancers, most strongly for gastric cancer but also for pancreatic cancer 26, 27 . The protective allele T for rs505922 is in complete LD (r 2 ¼ 1.0) with the O allele of the ABO locus, consistent with earlier reports showing increased risk of gastric and pancreatic cancer for individuals of the A and B blood groups. It is plausible that the single-base deletion that generates the O blood group underlies the association signal, but further mapping and laboratory work will be required to determine which variant(s) account for the observed association.
Genetic variation in the first intron of the ABO gene has also been associated with circulating levels of serum tumor necrosis factor alpha Figure 1 Manhattan plot of the P values in the pancreatic cancer GWAS. (a) Association with pancreatic cancer for the entire GWAS (12 cohort studies and the Mayo case-control study; Online Methods). (b) Results of the GWAS including only the 12 cohorts studies. Association was assessed using unconditional logistic regression adjusted for study, arm, age, sex, ancestry and the top five principal components of the population stratification analysis. The x axis represents chromosomal locations and the y axis shows P values on a logarithmic scale.
(TNFa) 28 , circulating levels of soluble intracellular adhesion molecule 1 (sICAM-1) 29 and plasma levels of alkaline phosphatase 30 . Although higher TNFa levels are associated with the common allele of rs505922, which is protective for pancreatic cancer in our study, the data concerning the relationship between blood groups and TNFa levels are inconsistent 28 . Furthermore, this region could be important for regulating circulating levels of sICAM-1, as rs507666 and rs505922 (located 170 bp apart) were recently reported to be associated with the amount of circulating ICAM-1 (ref. 29) . In addition, SNPs in the ABO locus, including rs657152, have been associated with plasma levels of liver-derived alkaline phosphatase 30 . Last, ABO antigen expression is altered in primary and metastatic pancreatic cancers compared with normal pancreatic tissues 31 . For rapidly fatal conditions, case-control studies are prone to distortion because they include survivors disproportionately. For variants unrelated to survival, case-control data are suitable for discovery and replication of risk-related markers. However, for variants related to survival, case-control studies yield biased estimates of Results from the unconditional logistic regression of the genotypes generated in the initial GWAS and the follow-up studies in a total of 3,891 individuals with pancreatic cancer and 4,001 controls. The analysis was adjusted for age in 10-year categories, sex, study, arm, ancestry and five principal components of population stratification. OR, odds ratio; Het, heterozygous; Hom, homozygous for minor allele. 
L E T T E R S
the association with pancreatic cancer risk. ABO variants seem to be unrelated to survival and show strong, similar signals in both cohort and case-control data.
We observed a genome-wide association with SHH (P ¼ 1.76 Â 10 À7 ) among cohorts that was not replicated in the follow-up in casecontrol studies (P ¼ 0.12), raising three possibilities: that the cohort finding is due to chance, that SHH is related to both survival and to risk or that the SNPs failed to replicate because of chance ( Table 1) . Because there is substantial evidence that SHH has a role in pancreatic carcinogenesis, further work is required to investigate this region 32 .
Pancreatic cancer is among the deadliest of cancers, with mortality rates approaching incidence rates 1 . As there are few known risk factors, improved diagnostics and a finer understanding of the molecular pathogenesis are urgently needed. Our findings have identified the contribution of genetic variation in the ABO locus of 9q34 to pancreatic carcinogenesis, a finding that supports an epidemiologic observation first made a half-century ago and recently confirmed 33 . We are now conducting a GWAS in the eight studies from stage 2 of this study and anticipate that this will bring the identification of additional loci associated to pancreatic cancer. The discovery of additional genetic risk variants for this highly lethal cancer could contribute to improvements in risk stratification, prevention, early detection and therapeutic approaches to pancreatic cancer.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Data access. The Cancer Genetic Markers of Susceptibility (CGEMS) data portal provides access to data for 558,542 SNPs in 3,835 individuals. Investigators from certified scientific institutions may access the portal after approval of their submitted Data Access Request.
Note: Supplementary information is available on the Nature Genetics website. rs10793959  rs11999677  rs4379511  rs4507838  rs6597612  rs7036324  rs7469576  rs9919007  rs4363269  rs8176749  rs8176746  rs2073824  rs512770  rs8176704  rs574347  rs2073828  rs8176694  rs657152  rs500498  rs505922  rs630014  rs568203  rs495828  rs13298002  rs500428  rs1752337  rs9411493  rs7025162  rs624960  rs4962043  rs554710  rs11244079  rs493014 135176984 Combined 16 , and the Women's Health Study (WHS) 17 . Each cohort that participated in PanScan had a defined population from whom blood or buccal cells were collected before the diagnosis of pancreatic cancer. Incident primary pancreatic adenocarcinoma cases were identified by self-report with subsequent medical record review, linkage with a cancer registry or both. Cases were defined as primary adenocarcinoma of the exocrine pancreas (ICD-O-3 code C250-C259). Non-exocrine pancreatic tumors (histology type 8150, 8151, 8153, 8155 and 8240) were excluded. We identified 1,770 incident cases among the cohorts as part of a nested case-control study. We selected an equal number of controls within their respective cohort. One control was matched per case based on calendar year of birth (±5 years), sex, broad category of race and ethnicity and DNA (blood or buccal cell). Each control was alive and free of pancreatic cancer on the calendar date that his or her matching case was diagnosed with pancreatic cancer. The NHS, HPFS, WHS and PHS cohorts also matched cases and controls based on smoking status. Four hundred individuals with pancreatic adenocarcinoma and 400 controls were included from the Mayo Clinic Molecular Epidemiology of Pancreatic Cancer Study 18 . The Molecular Epidemiology of Pancreatic Cancer study was initiated in 2000 and used an 'ultrarapid' case ascertainment system in which 495% of patients at the Mayo Clinic from Minnesota, Iowa, and Wisconsin who were suspected to have pancreatic cancer were approached. Among those with pancreatic cancer, 72% provided consent and a blood sample. Clinic controls were drawn from patients seeking general medical care and were frequency matched to cases on age, race, gender, and area of residence.
Eight case-control studies from the PANC4 consortium participated in a replication of promising SNPs from the initial scan: University of Toronto 19 Table 2) .
Each participating study obtained informed consent from study participants and approval from its Institutional Review Board. Each cohort study and the Mayo Clinic case-control study obtained Institutional Review Board certification, permitting data sharing in accordance with the US National Institutes of Health (NIH) Policy for Sharing of Data Obtained in NIH-Supported or -Conducted Genome-Wide Association Studies.
Genotyping and quality control. We selected 4,063 DNA samples (including 311 from buccal cells) for genotyping (representing 3,932 individuals). One hundred twenty-nine DNA samples were analyzed in duplicate.
Owing to the multitude of studies of varying sample sizes in PanScan, we compared the results of genotype clustering to verify goodness of fit, detect genotype discordances and monitor potential cluster heterogeneity. The genotype models evaluated included (i) default cluster definitions provided by Illumina, (ii) clusters estimated from each study separately, (iii) clusters estimated from each study separately using samples with 498% completion rates, calling the 'low-completion' samples using those cluster models, (iv) clusters estimated from all studies together using all samples, (v) clusters estimated from all studies together using samples with 498% completion rates, then calling the low-completion samples using those cluster models and (vi) clusters estimated from each study separately using samples with 498% completion rates, followed by grouping and reclustering studies that showed similar cluster metrics. Genotypes for low-completion samples were called using the corresponding cluster model. On the basis of completion rates and low discordance between known duplicate samples, the most rigorous clustering methods were (iii), (v) and (vi). Model (v) was chosen on the basis of parsimony.
We attempted 561,466 SNP genotype assays on the 4,063 DNA samples using the Human Hap500 Infinium Assay (Illumina). Samples with o98% completion after the second attempt were subsequently excluded. SNP assays with call rates o90% were excluded. We observed an average discordance rate of 0.017% for 139 pairs of duplicate DNA assays (including 129 plated duplicate samples).
Deviation from Hardy-Weinberg proportions were tested 34 in control samples (with CEU ancestry 40.80 by STRUCTURE) of each study ( Supplementary  Fig. 2) . No SNPs were excluded from analysis, as the tests for association are valid in the presence of departure from Hardy-Weinberg proportions.
Some participants with valid genotypes were excluded because of (i) unanticipated interstudy duplicates (n ¼ 14), (ii) completion rates o98% (n ¼ 219 samples corresponding to 74 participants), (iii) unexpected withinstudy duplicate (n ¼ 1) and (iv) ineligible samples (n ¼ 8). The final count of participants for the stage 1 association analysis was 1,896 cases and 1,939 controls (Supplementary Table 4) .
Assessment of population structure was performed with STRUCTURE 35 by seeding the genotypes from the PanScan studies with the reference HapMap genotypes (based on Build 22 for HapMap II with MAF45% in any of three HapMap populations) 36 . A set of 9,405 SNPs with r 2 o 0.004 was selected for this analysis [37] [38] [39] . A total of 59 participants (29 cases and 30 controls) were estimated to be of admixed origin with o80% similarity to CEU. No participants were excluded based on results from STRUCTURE but were assigned to the following categories for adjustment in the association analysis: European if CEU admixture portion was 480%, Asian if JPT/HCB admixture portion was 480% and 'other' if admixture with no one continental group was 480% (Supplementary Fig. 3 ). African American ancestry was defined based on self-report, with similarity to YRI ranging from 41% to 96%.
A principal component analysis (PCA) of DNA samples in this study (excluding inferred sib and half-sib pairs) was performed with EIGENSTRAT 40 . Five principal components were effective 41 for distinguishing significant population groups and were included as quantitative covariates to correct for genetic admixture.
Genotype data for the full scan was used to identify 144 participants with 60%-99% identity by state as potential relatives. Two sets of SNPs with pairwise r 2 o 0.004 were selected separately for Asian (13,905 SNPs) and non-Asian studies (9,405 SNPs) and run on PREST 42 to identify five unexpected full-sib pairs and two unexpected half-sib pairs (seven cases and seven controls), who were excluded from PCA but included in the association analysis.
TaqMan assays (ABI) were designed and optimized for ten SNPs in the three notable regions as well as for a technical replica assay for rs505922 (rs687621) because this SNP could not be optimized (96% genotype concordance with HapMap samples) as per SNP500Cancer.
For the fast-track replication study, 5,845 samples were genotyped, including 180 duplicate DNA samples for quality control purposes. Genotyping was performed using a multiplex integrated fluidic technology (Fluidigm Biomark) and individual TaqMan assays (ABI). During the follow-up replication genotyping, the opportunity arose to conduct a GWAS with the Illumina Infinium 610Quad. Because the same SNPs would be later genotyped, we completed genotyping only for the top ten ranked SNPs (a second GWAS is ongoing). Consequently, genotyping of some of the samples for the fast-track replication was performed with low quantities of DNA (reserving sufficient DNA for the GWAS). Sample completion ranged from 28.90% to 99.40% per study, and genotype completion rates per locus ranged from 57.7% to 99.8%. Overall genotype concordance between duplicate samples was 96.52%, indicating the reliability of the current fast-track replication results. Discordant genotypes between duplicates were set to 'missing' . A small proportion (0.2%) of samples genotyped in stage 2 were excluded, as they were unanticipated interstudy or intrastudy duplicates or had incomplete covariate data. The corresponding Infinium cluster plots for the ten SNPs are shown in Supplementary Figure 4 .
Association analysis. All association analyses were conducted using logistic regression, adjusted for age (in 10-year categories), sex, study, arm (for WHI, intervention versus observation), ancestry and five principal components of genetic structure. Each SNP genotype was coded as a count of minor alleles, with the exception of X-linked SNPs among males, which were coded as '2' if the participant carried the minor allele and '0' if he carried the major allele 25 . This log-linear odds model has near-optimal power across a wide range of alternative hypotheses, the main exception being rare recessive variants, for which we have limited power regardless of genotype coding 43 . A score test was performed on all genetic parameters in each model to determine statistical significance, with 1 d.f.
We analyzed each study separately and conducted two analyses pooling multiple studies: the first included all cohorts ('cohorts'); the second included all studies ('all'). We assessed heterogeneity in genetic effects across study using the Q and I 2 statistics 44 .
We selected for replication ten SNPs from the three most notable regions from the GWAS (based on two or more SNPs per region ranking in the top 25 SNPs) based on the results of the two pooled analyses. We tested association between pancreatic cancer and the replication SNPs by fitting logistic regression models and testing the estimated genetic effects using the GLU software package. We analyzed each study separately in addition to pooling all eight studies. Models were adjusted for age in 10-year intervals as well as for sex, selfreported race and study. Genotypes were coded as counts of minor alleles (1-d.f. trend test). Combined single-SNP analyses pooled stage 1 and stage 2 data sets and adjusted for study, arm, age, sex, race and top five principal components of population stratification. In stage 2 studies, principal components could not be calculated and were set to 0. Supplementary Table 5 provides the results of the stage 2 association analysis.
Data analysis and management used GLU (Genotyping Library and Utilities version 1.0), a suite of tools available as an open-source application for management, storage and analysis of GWAS data.
